Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Enterprise Value (2016 - 2025)

Lineage Cell Therapeutics' Enterprise Value history spans 16 years, with the latest figure at -$62.2 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 26.4% year-over-year to -$62.2 million; the TTM value through Dec 2025 reached -$62.2 million, down 26.4%, while the annual FY2025 figure was -$62.2 million, 26.4% down from the prior year.
  • Enterprise Value reached -$62.2 million in Q4 2025 per LCTX's latest filing, down from -$33.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$31.4 million in Q4 2023 to a low of -$98.5 million in Q4 2022.
  • Average Enterprise Value over 5 years is -$55.0 million, with a median of -$48.7 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: plummeted 217.54% in 2021, then skyrocketed 68.16% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$59.7 million in 2021, then crashed by 65.12% to -$98.5 million in 2022, then surged by 68.16% to -$31.4 million in 2023, then crashed by 56.7% to -$49.2 million in 2024, then decreased by 26.4% to -$62.2 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Enterprise Value are -$62.2 million (Q4 2025), -$33.5 million (Q3 2025), and -$43.6 million (Q2 2025).